MIND Study for Adults ages 55+ with Memory Concerns
Alzheimer's Therapeutic Research Institute Memory Improvement through Nicotine Dosing or Long-Term Nicotine Treatment of Mild Cognitive Impairment
This study enrolls adults ages 55-90 who have concerns about memory. The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to learn whether Nicotine absorbed through the skin through a daily nicotine patch improves attention, learning, and memory in folks with mild cognitive impairment.
You will attend up to 12 visits with the study team over about 2 years. You will wear a skin patch, containing either nicotine or placebo, for about 16 hours per day while participating. A placebo looks like the study drug but has no active ingredients. Neither you or the study team will know which group you are in. Study visits take place at UBMD Neurology outpatient locations in Western New York.
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function.
The study will enroll 300 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Adults ages 55-90.
Must be a non-smoker.
Must have a memory concern as reported by participant, study partner, or clinician.
Study Partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to most visits to answer questions about the participant.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.